Dr. Vignati is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8515 Olde Mill Circle West Dr
Indianapolis, IN 46260Phone+1 317-254-1686
Summary
- Dr. Louis Vignati received an undergraduate degree from the University of Pennsylvania, a graduate degree in organic chemistry from American University and a medical degree from Thomas Jefferson University. He completed his house staff training at the University of Vermont and Endocrine Fellowship at the Peter Bent Brigham Hospital and the Elliot P. Joslin Research Laboratory in Boston, Massachusetts.
He served as an officer in the USPHS in the Toxicology Branch of the National Institute of Health for Occupational Safety and Health. Dr. Vignati was senior physician at the Joslin Diabetes Center in Boston, Massachusetts. Dr. Vignati has been a principal investigator for numerous clinical trials and co-investigator for the DCCT (Diabetes Control and Complications Trial.
He was Distinguished Medical Fellow at Eli Lilly and Company and served as the Medical Director for development of early phase endocrine compounds. At Lilly he participated in the global development of therapies diabetes and obesity including Humalog, Recombinant Glucagon, and Forteo. Following his tenure at Lilly Dr. Vignati was Vice President, Medical of Marcadia Biotech until Roche acquired Marcadia. He served as the Vice president of Clinical development for Calibrium LLC. Currently is active as consultant for Pharmaceutical development.
Education & Training
- American UniversityM.S., Organic Chemistry, 1966
- University of PennsylvaniaB.A., 1964
- Brigham and Women's HospitalFellowship, Endocrinology, Diabetes, and Metabolism, 1975 - 1977
- University of Vermont Medical CenterResidency, Internal Medicine, 1973 - 1975
- University of Vermont Medical CenterInternship, Internal Medicine, 1970 - 1971
- Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1970
Certifications & Licensure
- IN State Medical License 1990 - 2025
- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Research Fellowship United States Public Health Service, 1975
- Meesy Foundation Scholarship Thomas Jefferson University, 1967
Publications & Presentations
PubMed
- 255 citationsReduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group.James H. Anderson, Rocco L. Brunelle, Veikko A. Koivisto, Andreas Pfützner, Michael E. Trautmann
Diabetes. 1997-02-01 - 472 citationsUnimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and HumansBrian Finan, Tao Ma, Nickki Ottaway, Timo D. Müller, Kirk M. Habegger
Science Translational Medicine. 2013-10-30 - 212 citationsThe Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes.Juan Pablo Frias, Edward J. Bastyr, Louis Vignati, Matthias H. Tschöp, Christophe Schmitt
Cell Metabolism. 2017-08-01
Journal Articles
- Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and HumansB. Finan, T. Ma, N. Ottaway, T. D. Muller, K. M. Habegger, K. M. Heppner, H. Kirchner, J. Holland, J. Hembree, C. Raver, S. H. Lockie, D. L. Smiley, V. Gelfanov, B. Ya..., Sci. Transl. Med., 1/1/2013
- Oral protein kinase C Beta inhibition using Ruboxistaurin: Efficacy, Safety, and Causes of Vision Loss Among 813 Patients (1,392 Eyes) with Diabetic Retinopathy in the...Aiello LP, Vignati L, Sheetz MJ, Zhi X, Girach A, Davis MD, Wolka AM, Shahri N, Milton RC; for the PKC-DRS and PKC-DRS2 Study Groups, 1/20/2011
- Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema Invest OphthalmolDavis MD, Sheetz MJ, Aiello LP, Milton RC, Danis RP, Zhi X, Girach A, Jimenez MC, Vignati L; PKC-DRS2 Study Group, Vis Sci, 1/1/2009
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Diabetic Macular Edema, Relationship of Visual Acuity to Involvement of the Center of the MaculaSheetz, Matthew J.; Aiello, Lloyd P.; Davis, Matthw D.; Milton, Roy C.; Arora, Vipin; Hu, Kuolung; Girach, Aniz;, Vignati, Louis, Diabetes, 1/1/2004
- Diabetic Retinopathy and Macular Edema Progression Rates in Recent Placebo-Controlled Clinical TrialsDavis, Matthew; Aiello, Lloyd; Milton, Roy; Sheetz, Matthew; Arora, Vipin; Vignati, Louis, PKC-DRS and PKC-DMES Study Groups, Diabetes, 1/1/2003
- Ruboxistaurin (RBX) Mesylate Treatment in Patients with Diabetic Peripheral Neuropathy (DPN) Improves Clinical Global Impression (CGI) and Correlates with Change in Pa...Bastyr, Edward III; Price Karen; Skljarevski, Vladimir; Lledo Alberto; Vignati, Louis, Diabetes, 1/1/2003
- Join now to see all
Other
- Sustained moderate visual loss as a predictive end point for visual loss in non-proliferative diabetic retinopathyA Girach, L P Aiello, R C Milton, M D Davis, R P Danis, X Zhi, M J Sheetz and L Vignati, Eye
1/7/2008 - Protein Conservation During Fasting: A Function of Triiodothyronine Levels: Transactions American Association of Physicians, Volume ICIVignati L, Finley R, Hagg S, Aoki TT
1/1/1978
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: